Intensified Total Neoadjuvant Therapy Shows Promise in Locally Advanced Rectal Cancer with 74.6% Five-Year Survival Rate

A long-term follow-up analysis of a prospective phase II trial has revealed promising outcomes for patients with locally advanced rectal cancer (LARC) treated with an intensified total neoadjuvant therapy (TNT) approach. The study, conducted between October 2015 and September 2019, demonstrated a five-year overall survival rate of 74.6% among treated patients.

The innovative treatment protocol combined targeted therapy agents (bevacizumab or panitumumab/cetuximab) with FOLFOXIRI (5-fluorouracil, leucovorin, oxaliplatin, and irinotecan) as induction chemotherapy, followed by intensified chemoradiotherapy using oxaliplatin and 5-fluorouracil before surgical resection.

Treatment Response and Survival Outcomes

The trial enrolled 28 patients with histologically confirmed LARC adenocarcinoma. Notably, 11 patients (39.3%) achieved a complete response (CR) to the treatment regimen. With a median follow-up period of 6.3 years, the study revealed a five-year disease-free survival (DFS) rate of 57.1% across all participants.

Complete responders showed particularly encouraging outcomes. Patients achieving CR demonstrated a five-year overall survival rate of 80.8%, compared to 70.1% in non-CR patients (p=0.07). More significantly, the five-year disease-free survival rate for CR patients reached 81.8%, substantially higher than the 41.2% observed in non-CR patients (p=0.015).

Clinical Implications

These findings suggest that intensified TNT could represent an important therapeutic advancement for LARC patients, particularly for those who achieve complete response. The marked improvement in disease-free survival for complete responders (81.8% vs 41.2%) highlights the potential value of this treatment approach in managing locally advanced rectal cancer.

The study's long-term follow-up data provides valuable insights into the durability of treatment response, though larger randomized trials may be needed to further validate these promising results. The significant difference in disease-free survival between complete and non-complete responders also emphasizes the importance of achieving complete response as a treatment goal in LARC management.